Extraordinary Shareholder’s Meeting - January 25, 2021

GENFIT to Present at Upcoming Investor Conferences and Host a PBC KOL Event

January 6, 2021
Supporting Materials:

Lille, France; Cambridge, MA; January 6, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that it will be presenting at the following upcoming investor conferences and host a Primary Biliary Cholangitis (PBC) KOL event for the financial community.

Investor Conferences

  • Oddo 24th BHF Forum, January 7 - 8, 2021;
  • Solebury Trout Management Access Event, January 6 – 15, 2021;
  • Invest Securities Biomed Event, January 26 - 27, 2021;
  • Leerink Annual Global Healthcare Conference, February 23 - 25, 2021.

PBC KOL EVENT for the financial community

GENFIT will host a KOL event on Primary Biliary Cholangitis (PBC), the disease targeted by its lead development candidate*, elafibranor, a dual PPAR a/d agonist. The event will feature presentations from GENFIT senior management and KOLs engaged in the management of patients with PBC. The program will focus on the PBC treatment landscape, potential new treatments for PBC, and the PBC commercial opportunity*. Two sessions will be organized, one in English and one in French. The event dates will be communicated shortly, and information will be available on the investor page of GENFIT’s corporate website, under the events section, at https://ir.genfit.com.

ABOUT GENFIT

 

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH.  NIS4™ technology has been licensed to LabCorp in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com

 

CONTACT

GENFIT | Investors

Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com

 

PRESS RELATIONS | Media

Hélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com

                     

 

 

* This press release was edited to reflect the fact that elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority